Elevation Wealth Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Elevation Wealth Partners’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.57K	Buy	+135	New	+$4.5K	﹤0.01%	1040

Other funds holding TEVA

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

AIIMS

Analyst IMS Investment Management Services Tel-Aviv, Israel $4.3B AUM 37.33% 1-Year Est. Return

UBP

Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return

FAF

Fjarde Ap-fonden Stockholm, Sweden $20.9B AUM 36.93% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Elevation Wealth Partners's TEVA Position: Q2 2026 in Review

Elevation Wealth Partners opened a new position in Teva Pharmaceuticals (TEVA) in Q2 2026: 135 shares worth $4.57K. The stake represents ﹤0.01% of the portfolio and ranks #1040 among its holdings.

208 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Elevation Wealth Partners held 135 shares of Teva Pharmaceuticals worth $4.57K as of Q2 2026.
Teva Pharmaceuticals was a new Elevation Wealth Partners position in Q2 2026.
Teva Pharmaceuticals made up ﹤0.01% of Elevation Wealth Partners's portfolio in Q2 2026, its #1040 holding.
208 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Elevation Wealth Partners's 13F filing for Q2 2026, filed 8 Jul 2026.